Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults

What is the cost-effectiveness of vaccination with a 2023-2024 COVID-19 mRNA vaccine in adults aged 18 years or older compared with no updated vaccination?This decision analytic modeling study in a simulated cohort projected that cost-effectiveness for a 2023-2024 COVID-19 mRNA vaccine using base case assumptions was cost saving for individuals older than 65 years, $25 787 per quality-adjusted life-year gained for those aged 50 to 64 years, and $115 588 per quality-adjusted life-year gained for those aged 18 to 49 years. Results were robust to changes in parameter inputs for the older age groups but sensitive to inputs for the younger age group.These findings suggest that vaccination is economically attractive for older adults but only under certain conditions for younger adults.

Corresponding Author: Lisa A. Prosser, PhD, University of Michigan, 2800 Plymouth Rd, NCRC Bldg 16, Ann Arbor, MI 48109 (lisapros@umich.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.